Clinical Trial

Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating cfDNA/NETs in Subjects With Pancreatitis

Study acronym: NUC-SAP1
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This is a single-centre, randomised-controlled, open-label, feasibility study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)/Neutrophil Extracellular Traps (NETs) in patients with severe acute pancreatitis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-21.
Trial Details
NCT Number NCT06566638
Lead Sponsor Liverpool University Hospitals NHS Foundation Trust
Collaborators: Santersus AG
Conditions Acute Pancreatitis, Organ Failure, Multiple
Enrollment 20 participants
Start Date 2025-12-01
Primary Completion 2026-12-05 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-20